AGI will be defined by its ability to autonomously formulate novel scientific hypotheses — effectively solving '100 years of biology' in a fraction of the historical time required, via continuous hypothesis-generation and experimental iteration.
Predictor: Demis Hassabis
Prediction text
AGI will be defined by its ability to autonomously formulate novel scientific hypotheses — effectively solving '100 years of biology' in a fraction of the historical time required, via continuous hypothesis-generation and experimental iteration. | First Isomorphic Labs approved drug from AI-designed molecule
Key catalyst: First Isomorphic Labs approved drug from AI-designed molecule
Watch events: Isomorphic drug pipeline; wet-lab automation milestones
Resolution evidence
AlphaFold 3, Isomorphic Labs, Atomic AI, Cradle all accelerating biology cycles; AlphaProteo de-novo protein design 2024; GNoME materials discovery.
Predictor: Demis Hassabis
Calibration plot (stated vs observed)
Evidence about this node from Demis Hassabis is multiplied by κ in /api/intake. Lower κ = less weight; floors at 0.10 (effectively silenced) and caps at 1.00 (full weight).
Reference class: agi_breakthrough_5y
Major capability discontinuity (e.g. AGI by named target year, 5-year horizon)
Tetlock-style outside view: at TRF=1 (just predicted), outside view dominates (w_in=0.3). At TRF=0 (deadline), inside view dominates (w_in=1.0). The blend regularizes overconfident inside views toward the historical base rate.
Probability over time
Milestone chain
- 2026-06-01 → 2027-06-30pendingIsomorphic Labs files first IND for AI-designed oncology drugHow: FDA IND acceptance and ClinicalTrials.gov registration of first Isomorphic Labs-originated oncology candidate, confirming the (revised) end-2026 Davos timelineSource: https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/conf 80%
- 2026-12-01 → 2028-06-30pendingIsomorphic Labs Phase 1 first-in-human dose administered for AI-designed cancer drugHow: Isomorphic Labs press release or peer-reviewed publication confirms first patient dosed in Phase 1 trial of AI-designed (de novo molecule) oncology compoundSource: https://creati.ai/ai-news/2026-02-14/deepmind-ai-cancer-drug-clinical-trials-2026-demis-hassabis/conf 70%
- 2027-01-01 → 2029-12-31pendingIsomorphic Labs / DeepMind reports drug discovery cycle time reduction below 12 months for at least one programHow: Peer-reviewed publication or Isomorphic disclosure shows hit-to-IND time under 12 months (vs. industry average 4-6 years) for at least one program, demonstrating Hassabis 'weeks not years' framing in practiceSource: https://www.isomorphiclabs.com/our-techconf 55%
- 2027-06-01 → 2032-12-31pendingFirst peer-reviewed publication where AI system autonomously formulates and validates a novel scientific hypothesis (no targeted prompting)How: Nature, Science, or Cell publication where AI system (DeepMind, Anthropic, OpenAI, Meta) is credited as primary author or hypothesis-generator for novel result in biology or chemistry, with experimental validationSource: https://fortune.com/article/demis-hassabis-deepmind-artificial-intelligence-google-alphabet-drug-discovery-isomorphic/conf 50%
- 2031-12-05pendingQ1 window check-in (25%)
- 2030-01-01 → 2034-12-31pendingFirst AI-designed therapeutic receives FDA approval (any indication)How: FDA NDA/BLA approval for therapeutic where lead molecule was de novo designed by AI system (Isomorphic, Insitro, Recursion, Insilico, or similar), per FDA approval letter and company disclosureSource: https://www.shashi.co/2026/04/isomorphic-labs-is-about-to-find-out-if.htmlconf 50%
- 2030-06-01 → 2036-12-31pendingCascade: AI-driven biology research accelerates such that publication-rate compression of ~10x reported in major journal studyHow: Bibliometric study in Nature, Science, or Cell quantifies that AI-augmented biology research labs publish at ~10x the rate of pre-AI baseline, OR DeepMind reports a 'compressed century' demonstration validating Hassabis '100 years of biology' framingSource: https://www.newsbytesapp.com/news/science/demis-hassabis-outlines-isomorphic-labs-to-speed-drug-discovery/tldrconf 40%
- 2033-11-07pendingQ2 window check-in (50%)
- 2035-10-11pendingQ3 window check-in (75%)
No downstream cascades — this prediction is a leaf in the dependency graph.
What if this resolves?
Click a button to clamp this prediction and run a Gibbs sample. Returns the predictions whose marginals shift most. ~30s per run; ideal for stress-testing "if X resolves, what else moves?"
Evidence chain
Network propagation neighbors
Top incoming (parents)
Edges that influence THIS node's belief
| Kind | Node | Their prob | P(c|s=T) | P(c|s=F) | Δ implied |
|---|---|---|---|---|---|
| killer | TK06 China-Taiwan Military Conflict | 8.0% | 0.050 | 0.600 | +0.044 |
| killer | TK03 AI Regulatory Moratorium (EU/US Capability Freeze) | 10.0% | 0.050 | 0.600 | +0.033 |
| killer | TK11 Autonomous Regulatory Block (Level 4 Halt) | 10.0% | 0.050 | 0.600 | +0.033 |
| killer | TK01 AGI Capability Plateau (2026-27 Training Stall) | 15.0% | 0.050 | 0.600 | +0.005 |
Top outgoing (children)
Predictions THIS node influences
No outgoing edges.
Prerequisites (6)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| correlate | S_AGI_MID_2029 | AGI mid: Kurzweil 2029 path | agi_general_capability | — |
| correlate | S_AGI_SLOW_2031 | AGI slow: Schmidt/Hassabis 5-10 year path | agi_general_capability | — |
| killer | TK01 | AGI Capability Plateau (2026-27 Training Stall) | — | — |
| killer | TK03 | AI Regulatory Moratorium (EU/US Capability Freeze) | — | — |
| killer | TK11 | Autonomous Regulatory Block (Level 4 Halt) | — | — |
| killer | TK06 | China-Taiwan Military Conflict | — | — |
Dependents (0)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| No dependents | ||||
Validations (1)
| Observed at | Status | By | Notes |
|---|---|---|---|
| 2026-04-29 | partial | thesis_timeline_v1.0_import | AlphaFold 3, Isomorphic Labs, Atomic AI, Cradle all accelerating biology cycles; AlphaProteo de-novo protein design 2024; GNoME materials discovery. |
Linked documents (10)
| Sim | Source | Title | Market prob | Polarity | Reviewed | Published |
|---|---|---|---|---|---|---|
| 0.604 | arxiv | An explainable hypothesis-driven approach to Drug-Induced Liver Injury with HADES | — | mentions | pending | 2026-05-04 |
| 0.599 | arxiv | Unsupervised Pattern Analysis in Japanese Veterinary Toxicology: A Regulatory-Compliant Framework for Cross-Species Risk Assessment | — | mentions | pending | 2026-06-04 |
| 0.598 | fda | FDA NDA219249: ITOVEBI (INAVOLISIB) — GENENTECH INC | — | mentions | pending | 2026-04-15 |
| 0.587 | fda | FDA ANDA208539: TICAGRELOR (TICAGRELOR) — MICRO LABS | — | mentions | pending | 2026-04-27 |
| 0.583 | fda | FDA ANDA215243: RAMELTEON (RAMELTEON) — MICRO LABS | — | mentions | pending | 2026-04-15 |
| 0.571 | fda | FDA ANDA219189: GALLIUM GA-68 GOZETOTIDE (GALLIUM GA-68 GOZETOTIDE) — IONETIX | — | mentions | pending | 2026-05-14 |
| 0.570 | fda | FDA ANDA218441: SITAGLIPTIN (SITAGLIPTIN) — BIOCON PHARMA LTD | — | mentions | pending | 2026-05-01 |
| 0.570 | fda | FDA ANDA090170: LAMOTRIGINE (LAMOTRIGINE) — UNICHEM LABS LTD | — | mentions | pending | 2026-04-09 |
| 0.563 | fda | FDA NDA212927: TIOCYSTIN (TIOPRONIN) — CASPER PHARMA LLC | — | mentions | pending | 2026-06-02 |
| 0.559 | fda | FDA ANDA218558: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — MICRO LABS | — | mentions | pending | 2026-05-07 |
Raw metadata
{
"nia": false,
"qty": "10-100x compression",
"mode": "FORECAST",
"role": "Cited-CEO",
"context": "Sharpens Hassabis's AGI-definition (CMQ_010) and biology-compression thesis beyond 247_033 (cure all disease in decade). The '100 years of biology' phrasing is Hassabis's signature framing.",
"to_year": 2040,
"conv_cues": "vivid compression metaphor; AGI-definition framing",
"direction": "HAPPEN",
"from_year": 2030,
"timeframe": "2030-2040",
"conv_level": "HIGH",
"milestones": [
{
"kind": "llm_pre_event",
"label": "Isomorphic Labs files first IND for AI-designed oncology drug",
"source": "https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/",
"status": "pending",
"weight": 0.4,
"ordinal": -11,
"source_id": null,
"confidence": 0.8,
"source_url": "https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/",
"expected_date": "2026-12-15",
"research_origin": "deep_research",
"expected_date_range": {
"to": "2027-06-30",
"from": "2026-06-01"
},
"measurement_criterion": "FDA IND acceptance and ClinicalTrials.gov registration of first Isomorphic Labs-originated oncology candidate, confirming the (revised) end-2026 Davos timeline"
},
{
"kind": "llm_pre_event",
"label": "Isomorphic Labs Phase 1 first-in-human dose administered for AI-designed cancer drug",
"source": "https://creati.ai/ai-news/2026-02-14/deepmind-ai-cancer-drug-clinical-trials-2026-demis-hassabis/",
"status": "pending",
"weight": 0.4,
"ordinal": -10,
"source_id": null,
"confidence": 0.7,
"source_url": "https://creati.ai/ai-news/2026-02-14/deepmind-ai-cancer-drug-clinical-trials-2026-demis-hassabis/",
"expected_date": "2027-09-15",
"research_origin": "deep_research",
"expected_date_range": {
"to": "2028-06-30",
"from": "2026-12-01"
},
"measurement_criterion": "Isomorphic Labs press release or peer-reviewed publication confirms first patient dosed in Phase 1 trial of AI-designed (de novo molecule) oncology compound"
},
{
"kind": "llm_pre_event",
"label": "Isomorphic Labs / DeepMind reports drug discovery cycle time reduction below 12 months for at least one program",
"source": "https://www.isomorphiclabs.com/our-tech",
"status": "pending",
"weight": 0.4,
"ordinal": -9,
"source_id": null,
"confidence": 0.55,
"source_url": "https://www.isomorphiclabs.com/our-tech",
"expected_date": "2028-07-01",
"research_origin": "deep_research",
"expected_date_range": {
"to": "2029-12-31",
"from": "2027-01-01"
},
"measurement_criterion": "Peer-reviewed publication or Isomorphic disclosure shows hit-to-IND time under 12 months (vs. industry average 4-6 years) for at least one program, demonstrating Hassabis 'weeks not years' framing in practice"
},
{
"kind": "scenario_signal",
"label": "Scenario fires: AGI mid: Kurzweil 2029 path",
"status": "pending",
"weight": 0.3,
"ordinal": -8,
"source_id": "S_AGI_MID_2029",
"expected_date": "2029-03-31",
"observed_date": null
},
{
"kind": "llm_pre_event",
"label": "First peer-reviewed publication where AI system autonomously formulates and validates a novel scientific hypothesis (no targeted prompting)",
"source": "https://fortune.com/article/demis-hassabis-deepmind-artificial-intelligence-google-alphabet-drug-discovery-isomorphic/",
"status": "pending",
"weight": 0.4,
"ordinal": -7,
"source_id": null,
"confidence": 0.5,
"source_url": "https://fortune.com/article/demis-hassabis-deepmind-artificial-intelligence-google-alphabet-drug-discovery-isomorphic/",
"expected_date": "2030-03-17",
"research_origin": "deep_research",
... (truncated)